GAMMA Investing LLC Takes Position in ABIVAX Société Anonyme (NASDAQ:ABVX)

GAMMA Investing LLC bought a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,976 shares of the company’s stock, valued at approximately $29,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BNP Paribas Financial Markets increased its position in shares of ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC grew its stake in ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after buying an additional 80,807 shares in the last quarter. abrdn plc increased its holdings in shares of ABIVAX Société Anonyme by 167.7% in the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock worth $3,645,000 after buying an additional 198,225 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after buying an additional 119,300 shares during the last quarter. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on ABVX. JMP Securities reiterated a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a research report on Friday, January 10th. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $38.67.

ABIVAX Société Anonyme Stock Down 5.4 %

Shares of ABIVAX Société Anonyme stock opened at $6.15 on Wednesday. The stock’s fifty day moving average is $8.22 and its 200 day moving average is $10.33. ABIVAX Société Anonyme has a one year low of $5.54 and a one year high of $17.02.

ABIVAX Société Anonyme Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.